Study to Understand Novel Biomarkers in Researching Dementia
Start Date
8/14/2024
Completion Date
12/1/2028
Summary
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Detailed Description
All participants who are eligible and provide informed consent will complete an initial study visit, which includes a research blood collection and cognitive assessments. Depending on the results of the cognitive assessments, participants will complete follow-up visits annually or biennially for additional cognitive testing, research blood collections, and potential clinical testing for Alzheimer's disease as determined by the participant's medical provider.
Eligibility Criteria
Age Range: 60 years to No maximum
Interventions
Clinical tau PET
Clinical amyloid test
Research blood collection
Cognitive assessments
Conditions
Locations
Washington University School of Medicine
St Louis, Missouri 63110
United States